Odonate Therapeutics Inc (OQ:ODT)

Business Focus: Pharmaceuticals

Apr 25, 2019 04:15 am ET
Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2019.
Apr 10, 2019 04:30 am ET
New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust, Comtech Telecommunications, and Odonate Therapeutics — Factors of Influenc
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Newmont Mining Corporation (NYSE:NEM), Johnson & Johnson (NYSE:JNJ), Portola...
Apr 02, 2019 04:05 am ET
Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today presented results of preclinical studies of tesetaxel, Odonate’s investigational, orally administered taxane, at the American A
Mar 28, 2019 04:30 am ET
Odonate Therapeutics Initiates CONTESSA TRIO
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of CONTESSA TRIO, a multi-cohort, multicenter, Phase 2 study of tesetaxel, Odonate’s investigational,
Mar 06, 2019 11:30 am ET
Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. Eastern Time.
Mar 04, 2019 11:30 am ET
Odonate Therapeutics Announces Initiation of CONTESSA 2, a Phase 2 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated CONTESSA 2, a multinational, multicenter, Phase 2 study of tesetaxel, Odonate’s investigational
Feb 28, 2019 03:30 am ET
Odonate Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the acceptance for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 of an abst
Feb 22, 2019 03:15 am ET
Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2018.
Feb 22, 2019 03:10 am ET
Detailed Research: Economic Perspectives on Omnicom Group, Venator Materials, Leidos, International Flavors & Fragrances, Odonate Therapeutics, and Aqua America — What Drives Growth in Today's Competi
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omnicom Group Inc. (NYSE:OMC), Venator Materials PLC (NYSE:VNTR),...
Nov 09, 2018 03:15 am ET
Consolidated Research: 2018 Summary Expectations for Senior Housing Properties Trust, NACCO Industries, Primo Water, Martin Marietta Materials, Iamgold, and Odonate Therapeutics — Fundamental Analysis
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Senior Housing Properties Trust (NASDAQ:SNH), NACCO Industries, Inc....
Oct 23, 2018 04:00 am ET
Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2018.
Oct 17, 2018 03:55 am ET
Report: Exploring Fundamental Drivers Behind Infinity Pharmaceuticals, AxoGen, MUELLER WATER PRODUCTS, MYR Group, RealNetworks, and Odonate Therapeutics — New Horizons, Emerging Trends, and Upcoming D
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), AxoGen, Inc. (NASDAQ:AXGN),...
Aug 20, 2018 03:40 am ET
Report: Exploring Fundamental Drivers Behind Ballard Power, Reading International, Odonate Therapeutics, Stitch Fix, Summit Therapeutics, and Cellectis S.A — New Horizons, Emerging Trends, and Upcomin
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ballard Power Systems, Inc. (NASDAQ:BLDP), Reading International Inc...
Jul 30, 2018 12:15 pm ET
Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2018.
Jun 05, 2018 04:20 am ET
New Research: Key Drivers of Growth for Helen of Troy, Macro Bank, American Software, Shire plc, KB Financial Group, and Odonate Therapeutics — Factors of Influence, Major Initiatives and Sustained Pr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Helen of Troy Limited (NASDAQ:HELE), Macro Bank Inc. (NYSE:BMA), American...
Jun 02, 2018 05:05 am ET
Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that results from a multicenter Phase 2 study of tesetaxel, administered orally as a single agent to patients with HER
May 31, 2018 05:00 am ET
Odonate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will present at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018, at 2:30 p.m. Easte
May 16, 2018 01:38 pm ET
Odonate Therapeutics Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that there will be two poster presentations on tesetaxel at the 2018 American Society of Clinical Oncology (ASCO) Annu
May 03, 2018 12:10 pm ET
Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2018.
Apr 10, 2018 03:45 am ET
Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences — Renewed Outlook, Key Drivers of Growt
NEW YORK, April 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ericsson (NASDAQ:ERIC), Toronto Dominion Bank (NYSE:TD),...
Mar 15, 2018 04:00 am ET
Report: Developing Opportunities within Odonate Therapeutics, Greenlight Reinsurance, Landmark Infrastructure Partners LP, GTx, First Mid-Illinois Bancshares, and iClick Interactive Asia Group — Futur
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Odonate Therapeutics, Inc. (NASDAQ:ODT), Greenlight Reinsurance,...
Feb 14, 2018 03:15 am ET
Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2017.
Dec 28, 2017 04:00 am ET
Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated
Dec 11, 2017 11:09 am ET
Odonate Therapeutics Announces Closing of Initial Public Offering
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $24.00 per share. The aggregate gross proceeds from the initial public offering to Odonate were approximately $150 million, before deducting underwriting discounts and commissions and offering expenses. The shares began trading on the
Dec 06, 2017 03:55 pm ET
Odonate Therapeutics Announces Pricing of Initial Public Offering
Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $24.00 per share for aggregate gross proceeds of approximately $150 million. All of the shares of common stock are being offered by Odonate. In addition, Odonate has granted the underwriters a 30-day option to purchase up to 937,5